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"<<	
>> 
!' (  Compare clinical effectiveness between tocilizumab and tumor necrosis factor 
inhibitors (TNFi) in patients with rheumatoid arthritis and inadequate response to 
conventional synthetic disease)modifying antirheumatic drugs initiating biologic therapy.  
)	(  Patients prescribed tocilizumab (intravenous) or TNFi were prospectively 
observed in routine clinical practice for 52 weeks across 158 sites in 26 countries. The 
primary observation was change from baseline in Disease Activity Score based on 28 joints–
erythrocyte sedimentation rate (DAS28)ESR) at week 24 using analysis of covariance for 
between)group comparison. Secondary end points included Clinical Disease Activity Index 
(CDAI) and patient)reported outcomes at weeks 24 and 52.  
(  Of 1216 patients, 35% initiated tocilizumab and 65% initiated TNFi. RA duration 
was shorter and disease activity and corticosteroid use were higher in tocilizumab patients. 
Tocilizumab)treated patients had greater improvement in DAS28)ESR at weeks 24 and 52 
(week 24 difference [95% confidence interval] in adjusted means: –0.831 [–1.086, –0.576]; 
p<0.001). Change from baseline in CDAI was also greater with tocilizumab (adjusted means 
difference: week 24, –3.48; week 52, –4.60; both p<0.001). Tocilizumab)treated patients had 
more improvement in Health Assessment Questionnaire–Disability Index than TNFi)treated 
patients (p<0.05). The cumulative probability of drug discontinuation at week 52 was lower 
with tocilizumab (15%) than TNFi (27%; p<0.001, unadjusted analysis). Unadjusted 
frequencies (events/100 patient)years) for tocilizumab and TNFi were 6.44 and 11.99 for 
serious adverse events, 1.98 and 5.03 for serious infections, and 0.74 and 0.77 for deaths, 
respectively. 
		(  Patients initiating tocilizumab experienced improved effectiveness and drug 
survival than those initiating TNFi in an observational setting.  
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"
*+	 	
• To date, comparative efficacy of the interleukin)6 receptor)alpha monoclonal 
antibody tocilizumab and tumor necrosis factor inhibitors (TNFi) for the treatment of 
rheumatoid arthritis has been investigated in a single head)to)head trial of tocilizumab 
monotherapy versus adalimumab monotherapy and network meta)analyses. 
• This prospective, observational, comparative effectiveness study provides the first 
real)world evidence of effectiveness and persistence on treatment for patients who 
initiated tocilizumab compared with those who initiated TNFi in routine clinical 
practice as measured by Disease Activity Score based on 28 joints–erythrocyte 
sedimentation rate (DAS28)ESR) and clinical disease activity index (CDAI).
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+!,-+!
Current American College of Rheumatology (ACR) and European League against 
Rheumatism (EULAR) guidelines recommend initiating treatment with biologic disease)
modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who 
have not responded to conventional synthetic DMARDs (csDMARDs) or who have high 
disease activity and features of poor prognosis (1,2). Many biologics are available for the 
treatment of RA; tumor necrosis factor inhibitors (TNFi), abatacept, and the interleukin)6 
receptor)α inhibitor tocilizumab are recommended; under certain circumstances, rituximab 
may be used (2). However, evidence is lacking regarding which biologics should be used and 
in what sequence.  
Only a few head)to)head clinical trials comparing biologics in patients with RA have been 
conducted to date. The randomized controlled phase 4 ADACTA trial in patients with RA 
who were intolerant of methotrexate or for whom continued therapy with methotrexate was 
inappropriate demonstrated superiority of tocilizumab monotherapy over adalimumab 
monotherapy for change in Disease Activity Score using 28 joints and the erythrocyte 
sedimentation rate (DAS28)ESR) from baseline to week 24. More tocilizumab)treated than 
adalimumab)treated patients achieved remission according to DAS28)ESR (DAS28 <2.6) 
and Clinical Disease Activity Index (CDAI ≤2.8) (3). The phase 3b AMPLE trial 
demonstrated similar clinical efficacy and inhibition of radiographic progression between 
abatacept and adalimumab in combination with methotrexate in patients with RA who had 
inadequate response to methotrexate (4). Rituximab was noninferior to TNFi treatment for 
change in DAS28)ESR in the open)label ORBIT trial in patients with RA who had 
inadequate response to csDMARDs (5). Comparison of effectiveness and drug survival 
between tocilizumab and TNFi in RA is limited to indirect comparison of clinical trial data 
and small observational studies (6)9).  
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The current study (ACT)iON) is the first prospective, large)scale, global, multicenter, 
comparative effectiveness study comparing initiation of intravenous tocilizumab with 
initiation of a TNFi in patients with RA as the first)line biologic treatment after inadequate 
response to csDMARDs in a real)world, clinical practice setting. Biologic therapy may be 
initiated in combination with csDMARDs or as monotherapy in clinical practice according to 
the decision of the treating physician; this study provides an opportunity to compare 
tocilizumab and TNFi therapy in combination with csDMARDs. 

)./!,"
"(ACT)iON was conducted at 158 sites in 26 countries (ClinicalTrials.gov, 
NCT01543503). Clinical effectiveness and safety outcomes of TNFi and tocilizumab were 
observed for 52 weeks of routine clinical practice after the initiation of first biologic therapy 
for the treatment of patients with RA. The study was observational; no additional diagnostic 
or therapeutic procedures were performed beyond routine clinical practice.  

0(The study included adult patients with moderate to severe RA, defined according to 
1987 ACR criteria (10), of at least 24 weeks’ duration who were nonresponders or who were 
intolerant of csDMARD therapy and whose treating physicians decided to initiate treatment 
with a TNFi or with intravenous tocilizumab in accordance with the local label (tocilizumab 
was initiated at 8 mg/kg in all patients because the study was not conducted in the United 
States or Canada, where the starting dose is 4 mg/kg (11,12)) as their first biologic. The study 
was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice 
and with the institutional review board/ethics committee. Patients provided written informed 
consent. 
Page 6 of 55
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
 7 
 

(Data were collected between February 9, 2012, and February 20, 2015. 
Patients might have initiated treatment before study start because the enrollment visit could 
occur up to 6 weeks after initiation of the first biologic. The primary observation was mean 
change from baseline in DAS28)ESR at week 24. Secondary outcome measures included 
mean change from baseline in DAS28)ESR at week 52, swollen joint count (SJC), tender 
joint count (TJC), remission rates according to DAS28)ESR and CDAI, and patient)reported 
outcomes (PROs), including Health Assessment Questionnaire–Disability Index (HAQ)DI).  
Safety was assessed throughout the study by monitoring adverse events (AEs), serious AEs 
(SAEs), abnormalities in laboratory assessments, and vital signs.  

"(The initial target sample size was 2000 patients, which was expected to 
provide 90% power to detect a between)groups difference of 0.3 DAS28 units. However, a 
slower than anticipated recruitment rate resulted in a final sample size of 1225 patients, 
which was expected to provide a detectable difference of approximately 0.4 DAS28 units. 
Safety was assessed in the safety population (all patients who received ≥1 dose of a TNFi or 
tocilizumab). The primary effectiveness analysis population included all patients in the safety 
population administered their first biologic within 60 days after the previous RA disease 
activity measurement.  
Missing values were not imputed for the primary analyses. Significance was determined as 
< 0.05 without correction for multiple testing. Differences in baseline characteristics were 
assessed using the Wilcoxon rank)sum test or chi)square test. Estimation of the primary 
outcome in the two treatment groups was based on an analysis of covariance (ANCOVA) 
model that included baseline DAS28)ESR as a covariate and concomitant csDMARDs and 
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country as factors. Given the selection and channeling bias possible in observational studies 
(13,14), supportive analyses were performed for DAS28)ESR and CDAI change from 
baseline to week 24 using matched)pair analysis based on the propensity score. This was 
computed using multiple logistic regression based on all relevant and evaluable baseline 
covariates (Supplementary Table S1). Post hoc sensitivity analyses were performed on the 
primary end point using any type of DAS28 to account for missing DAS28)ESR values. Data 
were restricted to patients with baseline disease activity assessments within 0 to 14 days 
before their first biologic treatment and used multiple imputation of missing week 24 
DAS28)ESR values in the same ANCOVA model as that for the primary analysis. Additional 
post hoc sensitivity analyses included adjustment for age, disease duration, seropositivity, 
steroid use at baseline, history of malignant tumor, and treatment in the ANCOVA model. 
Models similar to those for the primary analysis were used to analyze other end points such 
as CDAI and joint counts. Chi)square analysis was used for between)group comparisons of 
the proportion of patients in DAS28 remission and other categorical variables. Drug survival 
was analyzed according to the Kaplan)Meier method, and between)group comparisons were 
performed based on the log)rank test.  

."-1" 
0		(In total, 1216 patients initiated tocilizumab or TNFi therapy as their first 
biologic. Tocilizumab was initiated in 423 patients (35%) and TNFi in 793 patients (65%). 
The safety population was composed of the same 423 patients treated with tocilizumab and 
793 patients treated with TNFi. The primary effectiveness population included 390 patients 
treated with tocilizumab and 693 patients treated with TNFi (Supplementary Figure S1; 
Supplementary Table S2). Of the TNFi)treated patients, 315 (39.7%) received etanercept, 203 
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(25.6%) received adalimumab, 155 (19.5%) received certolizumab)pegol, 65 (8.2%) received 
infliximab, and 55 (6.9%) received golimumab. Excluding 21 screen failures, 162 (13.3%) 
patients withdrew from the study overall: 75 (17.7%) among patients who initiated 
tocilizumab as first biologic drug and 87 (11.0%) among patients who initiated TNFi. The 
most common reason was lost to follow)up, which occurred for 32 (7.6%) tocilizumab)
treated patients and 36 (4.5%) TNFi)treated patients. Nine (2.1%) tocilizumab)treated and 13 
(1.6%) TNFi)treated patients withdrew because of AEs, 4 (0.9%) tocilizumab)treated and 16 
(2.0%) TNFi)treated patients withdrew because of lack of efficacy, and 8 (1.9%) tocilizumab)
treated and 10 (1.3%) TNFi)treated patients withdrew consent. Overall, 34 (2.8%) patients 
withdrew for other reasons; 22 (5.2%) of them received tocilizumab and 12 (1.5%) received 
TNFi. Tocilizumab was initiated more often than TNFi as monotherapy (28.1% vs 16.0%, 
< 0.001; Table 1).  

(Baseline demographics, disease characteristics, and concomitant 
therapies were only partially similar between the groups. Patients initiating tocilizumab had 
shorter mean (standard deviation [SD]) disease duration than patients who initiated TNFi (7.8 
[7.3] vs 9.4 [9.0] years;  = 0.014). They also had slightly higher mean (SD) DAS28)ESR 
(5.8 [1.1] vs 5.5 [1.2];  = 0.030) and SJC (9.0 [6.2] vs 7.4 [5.3]; < 0.001) and more 
frequent oral corticosteroid use (60.5% vs 46.5%; < 0.001) than patients who started TNFi. 
Among combination therapy patients, the most common concomitant csDMARD at baseline 
was methotrexate (74.7%, tocilizumab)treated patients; 79.7%, TNFi)treated patients); in 
both groups, the median dose was 15 mg/week (Table 1). Additional baseline characteristics 
are shown in Supplementary Table S3. 
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Significant effects associated with the treatment choice (Supplementary Table S1) were  
country (United Kingdom and Spain were countries with clearly larger proportions of patients  
on TNFi), and intolerance was a reason for stopping the previous csDMARD (favoring the  
choice of tocilizumab: odds ratio [95% CI], 0.59 [0.42, 0.82];  = 0.002) and current alcohol  
intake (favoring TNFi: odds ratio [95% CI], 1.83 [1.16, 2.88];  = 0.0092).   
 
.

 (Patients who received tocilizumab as their first biologic had significantly  
higher change from baseline in DAS28)ESR to week 24 (primary end point) and week 52  
than those who initiated TNFi (treatment difference [95% CI]: week 24, –0.831 [–1.086, – 
0.575]; week 52 –0.910 [–1.204, –0.617]; both < 0.001; Figure 1). Results of the primary  
effectiveness analysis were confirmed by sensitivity analyses (Supplementary Table S4).  
Sensitivity analysis of change from baseline in any type of DAS28 (calculated using ESR, or  
C)reactive protein [CRP] if ESR was not available, and using DAS28 values entered by the  
investigator without each component), analysis of any type of DAS28 restricted to patients  
who had baseline disease activity assessments no longer than 2 weeks before their first  
biologic treatment and a model making use of multiple imputation confirmed the primary  
effectiveness results; ANCOVA accounting additionally for seropositivity, age, disease  
duration, steroid use at baseline, history of malignant tumor, and treatment, as well as  
propensity matching, also resulted in significantly higher change from baseline in DAS28) 
ESR to week 24 (Supplementary Tables S1 and S4). The smallest between)groups treatment  
difference in all these supportive analyses was –0.748. The mean (SD) treatment difference  
for the propensity score matched)pair analysis for DAS28)ESR was –1.05 (2.07;  < 0.001).  
Low patient numbers precluded viable effectiveness analysis of the data by monotherapy  
versus combination therapy with csDMARDs; only 28 patients treated with tocilizumab  
monotherapy and 42 treated with TNFi monotherapy were evaluable for the primary  
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effectiveness analysis. Analysis showed that among monotherapy patients, however, the 
treatment difference (95% CI) was not statistically significant for change from baseline in 
DAS28)ESR at week 24 or 52; monotherapy –0.287 (–1.194, 0.621;  = 0.530) at week 24 
and –0.598 (–1.289, 0.093;  = 0.089) at week 52 and combination therapy –0.950 (–1.220, –
0.680;  < 0.001) at week 24 and –0.972 (–1.297, 0.647; < 0.001) at week 52 
(Supplementary Table S5). 
 
Statistically significantly greater decreases from baseline to week 24 for patients who 
initiated tocilizumab compared with those who initiated TNFi were observed for ESR, CRP, 
and SJC (treatment differences [95% CI]: –13.23 [–15.51, –10.95], –6.67 [10.27, 3.07], and –
0.58 [–1.08, –0.08]; all < 0.05) (Table 2). There was no statistically significant difference 
in TJC between the treatment groups at week 24 in the primary models. At week 52, the 
treatment difference was significant for ESR (–12.65 [–15.42, –9.88]; < 0.001), SJC (–0.75 
[–1.24, –0.27];  = 0.002), and TJC (–1.22 [–2.04, –0.39];  = 0.004) but not for CRP.  
 
Decreases in CDAI and Simplified Disease Activity Index (SDAI) from baseline to weeks 24 
and 52 were also significantly greater in patients who initiated tocilizumab treatment 
compared with those who initiated TNFi (treatment differences [95% CI]: CDAI, –3.48 [–
5.48, –1.47] at week 24 and –4.60 [–6.71, 2.49] at week 52; SDAI, –3.23 [–5.81, –0.65] at 
week 24 and –3.25 [–6.12, –0.37] at week 52; all < 0.05). Significantly higher proportions 
of tocilizumab)treated than TNFi)treated patients were in remission at week 24 according to 
DAS28)ESR (44.7% vs 29.7%; < 0.001) and CDAI (22.4% vs 14.6%;  = 0.015) but not 
SDAI (21.3% vs 15.7%;  = 0.152). By week 52, significantly higher proportions of 
tocilizumab)treated than TNFi)treated patients had achieved remission according to all three 
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measures (Figure 2). Propensity score (calculated using logistic regression analysis with 
treatment group as the dependent variable and baseline factors as covariates) matched)pair 
analysis produced results comparable to those of the primary ANCOVA analysis of mean 
change from baseline to week 24 in CDAI; mean (SD) treatment difference –3.22 (20.29;  = 
0.0480) (Supplementary Table S6). There was a significant difference in improvement in 
PROs between patients who received tocilizumab as their first biologic and those who 
received TNFi, as demonstrated by a significantly greater decrease in HAQ)DI and 
Functional Assessment of Chronic Illness Therapy–Fatigue scores at week 24 (Table 2). 

 
,  (Termination of initial biologic therapy was reported for 14.9% of patients 
who started tocilizumab and 27.4% of those who started TNFi; of these patients, 38.1% and 
40.1%, respectively, terminated because of AEs and 23.8% and 48.8%, respectively, 
terminated because of lack of efficacy. It should be noted that patients could terminate their 
biologic therapy but remain in the study or could withdraw from the study without 
terminating their biologic therapy. Drug survival analysis, in which observations for patients 
who completed the study on the initial biologic therapy and those who withdrew prematurely 
from the study without a biologic discontinuation (eg, patients lost to follow)up) were 
censored, showed that drug survival was significantly higher with tocilizumab than with 
TNFi ( < 0.001; Figure 3). The probability of tocilizumab discontinuation was 9% (95% CI: 
6%, 12%) by week 24 and 15% (95% CI: 12%, 19%) by week 52. The cumulative probability 
of TNFi discontinuation was 15% (95% CI: 13%, 18%) at week 24 and 27% (95% CI: 24%, 
30%) by week 52. 
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"
(AEs and SAEs were reported in similar proportions and at similar rates per 100  
patient)years (PY) in patients who started tocilizumab and patients who started TNFi (Table  
3). Infections and infestations were the most common AEs and SAEs in both groups; serious  
infections were reported in 8 (1.9% [8 events; 1.98/100 PY]) tocilizumab)treated patients and  
26 (3.3% [39 events; 5.03/100 PY]) TNFi)treated patients (lower respiratory tract infection in  
6 TNFi)treated patients and no tocilizumab)treated patients, pneumonia in 6 TNFi)treated  
patients and 2 tocilizumab)treated patients). Three patients in the tocilizumab group died (2  
of pneumonia, 1 of cardiac failure), and 6 patients in the TNFi group died (fecal peritonitis  
and multiorgan failure; surgical graft infection and sepsis; metastatic neoplasm and  
cerebrovascular accident; sepsis; metastatic neoplasm; pneumonia and pericardial effusion).  
Two deaths from pneumonia (1 in each group) were deemed related to treatment according to  
the investigator. Further details of the deaths can be found in Supplementary Table S7.  
Numerical differences were observed in the incidence of patients experiencing shifts in  
neutrophil counts, liver transaminase levels, or lipid profile parameters from normal at  
baseline to abnormal at week 24 or 52 between the treatment groups, but no difference was  
seen between weeks 24 and 52 for the individual treatment groups (Supplementary Table S8).  
  
,+"-""+! 
This is the first large)scale, multinational, prospective study to present real)life data on the  
use and survival of first)line intravenous tocilizumab and TNFi initiated in RA patients with  
inadequate response to csDMARDs. Reflecting the observational nature of the study, there  
were no predefined interventions; the decision to initiate tocilizumab or TNFi was not based  
on protocol but on a decision made between the physician and the patient.   
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Significantly greater improvement in DAS28)ESR was seen at weeks 24 (primary end point)  
and 52 for patients who initiated tocilizumab as their first)line biologic compared with those  
who initiated TNFi. Since neither physicians nor patients were blinded to ESR or CRP  
results, there is a potential bias for overestimation of the effectiveness of tocilizumab  
influenced by changes in these markers of inflammation. Significantly greater improvement  
in CDAI was also observed for the tocilizumab group compared with the TNFi group.  
Calculation of the CDAI does not include the acute phase reactants CRP or ESR, suggesting  
that DAS28 results were not solely influenced by the effect of inhibition of IL)6 signaling  
with tocilizumab on acute phase reactants. Significantly higher proportions of tocilizumab) 
treated patients than TNFi)treated patients achieved remission according to CDAI criteria  
(CDAI ≤2.8) at weeks 24 and 52, but it should be noted that for SDAI remission (SDAI  
≤3.3), which does include calculation of CRP, the difference between tocilizumab and TNFi  
was significant only at week 52. Data on physical function, pain, and fatigue, though  
sometimes available in a minority of patients, were also consistent with the observation of  
greater effectiveness of tocilizumab. Tocilizumab was initiated as monotherapy more often  
than TNFi; however, the small number of patients in the primary effectiveness population  
prevented meaningful analysis of its effectiveness as monotherapy compared with  
combination therapy. The effectiveness of tocilizumab monotherapy compared with TNFi  
monotherapy would have to be investigated in a larger patient cohort.   
Comparison between results of the current study and the published literature should account  
for differences in patient populations, study designs, and patterns and durations of treatment.  
Nevertheless, effectiveness results observed with tocilizumab in reports from clinical practice  
support the results of our study. For example, in ACT)SURE, an open)label study of  
csDMARD–inadequate responders treated with tocilizumab in clinical practice (15), 6)month  
CDAI and SDAI remission rates were 21.1%, and 24.2%, respectively. In the current study,  
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they were 22.4%, and 21.3%, respectively. DAS28 remission rates in ACT)SURE (61.6%)  
were higher than in the current study (44.7%). Effectiveness data for TNFi agents are  
available from national registry databases. In the CORRONA registry, RA patients who  
started treatment with TNFi had a DAS28)ESR remission rate of 29.3% and a CDAI  
remission rate of 16.2% after 12 months (16). In the US Veterans Affairs Rheumatoid  
Arthritis (VARA) registry, the mean change from baseline in DAS28 after initiation of TNFi  
ranged from –0.77 to –1.20 (17), consistent with the mean change in the current study. The  
CORRONA and VARA registries collect data from patients in the United States, whereas the  
current study did not include US patients. ADACTA is the only head)to)head trial to date  
comparing tocilizumab with a TNFi (adalimumab); it demonstrated the superior improvement  
in DAS28)ESR over 6 months with tocilizumab. Network meta)analyses of randomized  
controlled trial data have also been performed to investigate relative efficacies of biologic  
therapies in patients with RA. Comparable ACR response rates have been found between  
tocilizumab and TNFi agents in combination with DMARDs (18)20). DAS28 remission rates  
may be higher for tocilizumab compared with abatacept, but this could be a result of the  
direct effect of tocilizumab on CRP levels (18)These network meta)analysis results are in  
contrast to the results of the current study, which showed better effectiveness for tocilizumab  
than TNFi (primarily in combination with DMARDs) as measured by DAS28)ESR and  
CDAI. Given the conflicting results between the literature and the current study and the  
limitations of comparing studies with different trial designs in network meta)analyses,  
prospective randomized trials are needed before robust conclusions can be drawn.  
Patients who initiated tocilizumab in the current study had higher drug survival rates than  
those who initiated TNFi, which may be related to differences observed in clinical  
effectiveness. The proportion of patients who remained on tocilizumab during this study  
(85.1%) is consistent with previously reported 6)month tocilizumab survival rates in clinical  
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practice in the ACT)UP study (82.7%) (21). Similarly, the proportion of patients who 
remained on TNFi (72.6%) was consistent with the proportion reported in the CORRONA 
registry after 12 months of TNFi therapy (72%) (16). Comparison in an Australian health 
care database of biologics for the treatment of RA suggested that patients may be more 
persistent with tocilizumab and abatacept initiated as the first biologic therapy than with 
subcutaneous TNFi agents. Combination therapy with methotrexate improved persistence 
with abatacept and subcutaneous TNFis but not with tocilizumab (22). 
The safety profiles of tocilizumab and TNFi were comparable to the safety profiles reported 
in clinical trials and clinical practice (15,21,23)28). A recent Japanese prospective cohort 
study (29) comparing the safety of tocilizumab and TNFi in clinical practice reported that the 
risks for SAEs and serious infections were not significantly different during the first year of 
treatment when adjusted for baseline covariates.  
Results of this study should be interpreted with an understanding of the limitation of potential 
biases associated with observational studies, including channeling bias. Confounding was 
addressed in a set of analyses adjusting for potential response predictors, including propensity 
score–based matching. All these analyses supported the key findings of the study. Results of 
the propensity score–based matched)pair analyses were comparable to those of the primary 
analysis for both DAS28)ESR and CDAI. Among other limitations were the amount of 
missing data for the effectiveness analysis (likely because of the observational nature of the 
study), the fact that DAS28)ESR was not used systematically in all centers (some centers 
used CRP for the calculation of DAS28), and the fact that delayed initiation of a prescribed 
treatment might have contributed to the lack of data for some baseline variables. 
Nevertheless, supportive efficacy analyses using end points with fewer missing values, 
including DAS28)CRP, and using imputation of missing data provided comparable results. 
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In conclusion patients in the ACT)iON observational study who initiated tocilizumab as their  
first biologic therapy after failure of csDMARDs experienced better drug survival and better  
improvements in DAS28)ESR, SJC, CDAI, and physical function than those who initiated  
TNFi. Additional prospective randomized controlled trials may be required to confirm these  
findings.  
 
 
  
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 6
789:

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
Age, years, mean (SD) 54.3 (12.8) 55.2 (13.1) 0.171
n
 
Disease duration, years, mean (SD) 7.8 (7.3) 9.4 (9.0) 0.014
n
 
DAS28)ESR, mean (SD)
a
 5.8 (1.1)
e
 5.5 (1.2)
j
 0.030
n
 
SJC, mean (SD)
a
 9.0 (6.2)
f
 7.4 (5.3)
k
 <0.001
n
 
TJC, mean (SD)
a
 12.1 (6.9)
g
 12.1 (7.6)
 k
 0.688
n
 
CDAI, mean (SD)
a
 33.0 (13.5)
h
 31.2 (13.2)
l
 0.077
n
 
HAQ)DI, mean (SD)
a
 1.5 (0.7)
e
 1.5 (0.7)
m
 0.968
n
 
Initiated biologic as monotherapy, n (%) 119 (28.1) 127 (16.0) <0.001
o
 
Initiated biologic in combination with 
csDMARDs, n (%) 
312 (73.8) 679 (85.6) 
– 
MTX, n (%)
b
 [median dose, mg/week]
c
 233 (74.7) 
[15.0] 
541 (79.7) 
[15.0] 
– 
Hydroxychloroquine, n (%)
b
 70 (22.4) 179 (26.4) – 
Leflunomide, n (%)
b
 73 (23.4) 124 (18.3) – 
Sulfasalazine, n (%)
b
 37 (11.9) 122 (18.0) – 
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Oral corticosteroid use, n (%)
d
 256 (60.5)  369 (46.5)  <0.001
o
 
Oral corticosteroid dose, mg/day mean (SD)d 8.3 (5.55)i 7.3 (5.31)l –
History of comorbid conditions, n (%)    
Other autoimmune disease 32 (7.6) 41 (5.2) 0.205p 
Overlap syndrome 10 (2.4) 12 (1.5) 0.060
p
 
Chronic hepatic impairment 11 (2.6) 27 (3.4) 0.774p 
Severe and/or progressive infection 12 (2.8) 22 (2.8) 0.709p 
Central nervous system demyelination 5 (1.2) 3 (0.4) 0.178p 
Severe immunosuppression 0 (0.0) 2 (0.3) 0.518p 
Malignant tumor 20 (4.7) 12 (1.5) 0.005
p
 
Lymphoproliferative syndrome 1 (0.2) 0 (0.0) 0.016p 
Angina/other heart disease 51 (12.1) 120 (15.1) 0.327p 
Other clinically significant comorbidities 258 (61.0) 512 (64.6) 0.451p 
aPrimary effectiveness population.  
bPercentages based on number of patients who initiated biologic in combination with 
csDMARDs. 
cFor MTX dose: TCZ, n = 233; TNFi, n = 538.  
dPrednisone equivalent.  
en = 230. fn = 352. gn = 353. hn = 238. in = 248. jn = 402. kn = 621. ln = 358. mn = 408.  
nBased on Wilcoxon rank)sum test.  
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o
Based on chi)square test for comparison of monotherapy and combination therapy between 
both treatment groups. 
pBased on Fisher exact test. 
CDAI, Clinical Disease Activity Index; DAS28, Disease Activity Score using 28 joints; 
csDMARD, conventional synthetic disease)modifying antirheumatic drug; ESR, erythrocyte 
sedimentation rate; HAQ)DI, Health Assessment Questionnaire‒Disability Index; MTX, 
methotrexate; SD, standard deviation; SJC, swollen joint count; TCZ, tocilizumab; TJC, 
tender joint count; TNFi, tumor necrosis factor inhibitor.
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3<>A+5
ESR –22.73  
(–24.72, –
20.75) 
n = 225 
–9.50  
(–11.11, –
7.89) 
n = 456 
–13.23  
(–15.51, –
10.95) 
p<0.001 
–21.52  
(–23.88, –
19.16) 
n = 215 
–8.87  
(–10.87, –
6.87) 
n = 411 
–12.65  
(–15.42, –
9.88) 
 < 0.001 
CRP –11.01  
(–14.13, –
7.88) 
n = 177 
–4.33  
(–6.86, –
1.81) 
n = 396 
–6.67  
(–10.27, –
3.07) 
p < 0.001 
–6.33  
(–10.52, –
2.14) 
n = 173 
–5.22  
(–8.71, –
1.72) 
n = 348 
–1.12  
(–6.07, 
3.84) 
 = 0.66 
SJC –5.70  
(–6.12, –
5.27) 
n = 288 
–5.12  
(–5.48, –
4.76) 
n = 554 
–0.58  
(–1.08, –
0.08) 
p = 0.024 
–6.31  
(–6.72, –
5.90) 
n = 258 
–5.56  
(–5.91, –
5.21) 
n = 503 
–0.75  
(–1.24, –
0.27) 
 = 0.002 
TJC –7.92  
(–8.59, –
7.25) 
n = 289 
–7.30  
(–7.87, –
6.74) 
n = 554 
–0.62  
(–1.41, 
0.17) 
p = 0.123 
–8.42  
(–9.12, –
7.72) 
n = 259 
–7.21  
(–7.80, –
6.61) 
n = 501 
–1.22  
(–2.04, –
0.39) 
 = 0.004 
CDAI –20.25  
(–21.93, –
–16.78  
(–18.28, –
–3.48  
(–5.48, –
–22.85  
(–24.63, –
–18.25  
(–19.82, –
–4.60  
(–6.71, –
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18.57) 
n = 176 
15.27) 
n = 286 
1.47) 
p < 0.001 
21.06) 
n = 162 
16.67) 
n = 267 
2.49) 
 < 0.001 
SDAI –21.39  
(–23.67, –
19.12) 
n = 93 
–18.16  
(–20.05, –
16.28) 
n = 193 
–3.23  
(–5.81, –
0.65) 
p = 0.014 
–22.29  
(–24.79, –
19.80) 
n = 91 
–19.05  
(–21.13, –
16.97) 
n = 169 
–3.25  
(–6.12, –
0.37) 
 = 0.027 
HAQ)DI –0.59  
(–0.69, –
0.49) 
n = 169 
–0.45  
(–0.54, –
0.35) 
n = 301 
–0.15  
(–0.27, –
0.02) 
p = 0.020 
–0.59  
(–0.71, –
0.48) 
n = 152 
–0.43  
(–0.54, –
0.32) 
n = 255 
–0.16  
(–0.30, –
0.03) 
 = 0.020 
FACIT)
Fatigue 
–7.15  
(–10.00, –
4.30) 
n = 64 
–3.26  
(–6.28, –
0.24) 
n = 86 
–3.89  
(–7.46, –
0.33) 
p = 0.032 
–4.57  
(–7.82, –
1.31) 
n = 50 
–1.78  
(–5.10, 
1.54) 
n = 77 
–2.79  
(–6.76, 
1.19) 
= 0.168 
Pain VAS –29.31  
(–32.92, –
25.69) 
n = 204 
–23.65  
(–26.66, –
20.63) 
n = 378 
–5.66  
(–9.91, –
1.41) 
p = 0.009 
–32.96  
(–36.71 –
29.20) 
n = 183 
–23.16  
(–26.39, –
19.92) 
n = 336 
–9.80  
(–14.25, –
5.36) 
 < 0.001 
Data are adjusted means (95% CI). n values are the number of evaluable patients included in 
the ANCOVA model. 
ANCOVA, analysis of covariance; CDAI, Clinical Disease Activity Index; CI, confidence 
interval; CRP, C)reactive protein; ESR, erythrocyte sedimentation rate; FACIT, Functional 
Assessment of Chronic Illness Therapy; HAQ)DI, Health Assessment Questionnaire‒
Disability Index; MTX, methotrexate; SDAI, Simplified Disease Activity Index; SJC, 
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swollen joint count; TCZ, tocilizumab; TJC, tender joint count; TNFi, tumor necrosis factor 
inhibitor; VAS, Visual Analog Scale.
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Exposure, PY 403.7 775.8 1179.5 
AEs, n (%) 
[no. of events] 
No. of events/100 PY 
208 (49.2) 
[501] 
124.10 
449 (56.6) 
[1011] 
130.32 
657 (54.0) 
[1512] 
128.19 
AEs leading to withdrawal, n (%) 
[no. of events] 
No. of events/100 PY 
9 (2.1) 
[9] 
2.23 
13 (1.6) 
[19] 
2.45 
22 (1.8) 
[28] 
2.37 
AEs of special interest, n (%) 34 (8.0) 42 (5.3) 76 (6.3) 
Infections, n (%) 88 (20.8) 205 (25.9) 293 (24.1) 
SAEs, n (%) 
[no. of events] 
No. of events/100 PY 
22 (5.2) 
[26] 
6.44 
64 (8.1) 
[93] 
11.99 
86 (7.1) 
[119] 
10.09 
Serious infections, n (%) 
[no. of events] 
No. of events/100 PY 
8 (1.9) 
[8] 
1.98 
26 (3.3) 
[39] 
5.03 
34 (2.8) 
[47] 
3.98 
Deaths, n (%) 
No. of events/100 PY 
3 (0.7) 
0.74 
6 (0.8) 
0.77 
9 (0.7) 
0.76 
AEs of special interest by SOC and preferred term, n (%)
a
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Gastrointestinal disorders 0 3 (0.4) 3 (0.2) 
Upper gastrointestinal 
hemorrhage 
0 2 (0.3) 2 (0.2) 
General disorders and 
administration site conditions 
1 (0.2) 4 (0.5) 5 (0.4) 
Injection site reaction 0 2 (0.3) 2 (0.2) 
Immune system disorders 3 (0.7) 4 (0.5) 7 (0.6) 
Hypersensitivity 2 (0.5) 3 (0.5) 5 (0.4) 
Infections and infestations 9 (2.1) 20 (2.5) 29 (2.4) 
Gastroenteritis 0 2 (0.3) 2 (0.2) 
Lower respiratory tract infection 0 3 (0.4) 3 (0.2) 
Pneumonia 2 (0.5) 6 (0.8) 8 (0.7) 
Urinary tract infection 0 2 (0.3) 2 (0.2) 
Injury, poisoning, and procedural 
complications 
2 (0.5) 1 (0.1) 3 (0.2) 
Infusion)related reaction 2 (0.5) 0 2 (0.2) 
Investigations 6 (1.4) 2 (0.3) 8 (0.7) 
ALT increased 2 (0.5) 0 2 (0.2) 
Transaminases increased 4 (0.9) 1 (0.1) 5 (0.4) 
Neoplasms benign, malignant, and 2 (0.5) 3 (0.4) 5 (0.4) 
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unspecified (including cysts and 
polyps) 
Metastatic neoplasm 0 2 (0.3) 2 (0.2) 
Nervous system disorders 2 (0.5) 4 (0.5) 6 (0.5) 
Cerebrovascular accident 0 2 (0.3) 2 (0.2) 
Skin and subcutaneous tissue 
disorders 
9 (2.1) 3 (0.4) 12 (1.0) 
Dermatitis allergic 0 2 (0.3) 2 (0.2) 
Rash 6 (1.4) 0 6 (0.5) 
aAEs reported in >1 patient in either treatment group. 
AE, adverse event; ALT, alanine aminotransferase; n, number of patients with event; PY, 
patient)years; SAE, serious adverse event; SOC, system organ class; TCZ, tocilizumab; 
TNFi, tumor necrosis factor inhibitor. 
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1

2Adjusted mean change from baseline to weeks 24 (primary end point) and 52 in 
DAS28)ESR (primary effectiveness population – all patients). Analyses were based on 
ANCOVA models, with changes from baseline in DAS28)ESR at week 24 or 52 as 
dependent variables, country (week 24 analysis) and treatment as fixed effects, and DAS28)
ESR at baseline as a covariate. ANCOVA, analysis of covariance; CI confidence interval; 
DAS28, Disease Activity Score using 28 joints; ESR, erythrocyte sedimentation rate; TCZ, 
tocilizumab; TNFi, tumor necrosis factor inhibitor.  

9Proportions of patients achieving remission at weeks 24 and 52 according to 
DAS28)ESR, CDAI, and SDAI criteria (primary effectiveness population – all patients; 
unadjusted analysis). * < 0.001 and † < 0.05 for TCZ vs TNFi (chi)square test). CDAI, 
Clinical Disease Activity Index; DAS28, Disease Activity Score using 28 joints; ESR, 
erythrocyte sedimentation rate; SDAI, Simplified Disease Activity Index; TCZ, tocilizumab; 
TNFi, tumor necrosis factor inhibitor. 
 
:Drug survival on tocilizumab and TNFi (safety population – all patients; 
unadjusted analysis) based on Kaplan)Meier curve of time to discontinuation of biologic 
therapy. Patients for whom biologic was not discontinued were censored at the study day of 
termination.  values were based on log)rank test. TCZ, tocilizumab; TNFi, tumor necrosis 
factor inhibitor. 
 
""2Patient disposition (A) and evaluable patients (B). DAS28, 
Disease Activity Score based on 28 joints; ESR, erythrocyte sedimentation rate; TCZ, 
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tocilizumab; TJC, tender joint count; TNFi, tumor necrosis factor inhibitor. 
a
Excludes screen 
failures. Patients could have more than 1 reason for discontinuing the study. 
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